GSK plc
- Open
- 51.11
- Day high
- 51.26
- Day low
- 50.61
- Prev close
- 50.25
- Volume
- 905K
- Mkt cap
- $101.4B
- P/E (TTM)
- 15.6
- EPS (TTM)
- $3.25
- P/B
- 4.3
- P/S
- 2.3
- Yield
- 3.59%
- Per share
- $1.82
GSK plc (GSK) is a Healthcare company listed on NYSE. The stock is up 29% over the past year. Drillr has 2 published research articles covering GSK.
GSK plc (GSK) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
GSK earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 28, 2026 | $1.26 | $1.36 | +7.5% | $11.2B | +1.7% |
| Apr 29, 2026 | $1.16 | $1.24 | +6.9% | $10.3B | +0.7% |
| Feb 4, 2026 | $0.64 | $0.68 | +6.3% | $8.5B | +10.2% |
| Oct 29, 2025 | $1.26 | $1.48 | +17.5% | $8.5B | +0.8% |
| Jul 30, 2025 | — | $0.96 | — | $10.9B | — |
| Apr 30, 2025 | $1.08 | $1.13 | +4.6% | $9.7B | +22.1% |
| Feb 5, 2025 | $0.44 | $0.59 | +34.1% | $10.2B | +6.5% |
| Oct 30, 2024 | $1.16 | $1.27 | +9.5% | $10.5B | +3.9% |
| Jul 31, 2024 | $1.00 | $1.09 | +9.0% | $10.0B | +3.3% |
| Jan 31, 2024 | $0.76 | $0.72 | -5.3% | $9.2B | -4.4% |
| Nov 1, 2023 | $1.09 | $1.26 | +15.6% | $10.2B | +8.6% |
| Jul 26, 2023 | $0.87 | $0.97 | +11.5% | $9.9B | +12.8% |
GSK research & analysis
GSK Stock: How the $9B Nuvalent Deal Reshapes Pipeline
The $9B Nuvalent deal lifts GSK net leverage to roughly 2.7x EBITDA but fills two oncology pipeline gaps. Risk-adjusted NPV at $10-12B supports the price.
NUVLNUVL Stock: Why GSK's $9B Takeover Talks Matter
NUVL at $88.49 implies 25-35% probability the rumored $130-135 GSK deal closes. ROS1 and ALK CNS programs fit GSK pipeline gaps.
NUVL
GSK plc company profile
Overview
GSK plc (LSE:GSK) is a British multinational pharmaceutical and biotechnology company founded in 1715, making it one of the world's oldest pharmaceutical companies. The company was formed through a series of mergers, most notably the 2000 merger of Glaxo Wellcome and SmithKline Beecham, and changed its name from GlaxoSmithKline plc to GSK plc in May 2022. Headquartered in Brentford, United Kingdom, GSK has evolved from a traditional pharmaceutical company into a focused biopharmaceutical enterprise specializing in vaccines and specialty medicines. The company operates globally with significant presence in the United States, Europe, and emerging markets, dedicating its efforts to preventing and treating diseases through innovative research and development.
Business
GSK operates as a biopharmaceutical company focused on two primary business segments that together generated £39.9 billion in revenue for 2024. The company has strategically transformed itself from a broad-based pharmaceutical manufacturer into a specialized developer and manufacturer of vaccines and innovative medicines. Vaccines Business represents GSK's largest segment, generating approximately 23% of total revenue. This division develops and manufactures vaccines for various diseases including shingles (Shingrix), respiratory syncytial virus or RSV (Arexvy), meningitis, influenza, and pediatric vaccines. Vaccines work by training the immune system to recognize and fight specific diseases before infection occurs. GSK's vaccine portfolio includes both preventive vaccines for healthy individuals and therapeutic vaccines for treatment. The company has particular strength in adult vaccines, an area that has historically been underserved compared to pediatric immunizations. Specialty Medicines accounts for roughly 37% of revenue and represents GSK's fastest-growing segment, expected to exceed 50% of total sales by 2031. This division focuses on four key therapeutic areas: HIV treatments (including long-acting injectable therapies like Cabenuva and prevention treatments like Apretude), oncology medications (including Blenrep for multiple myeloma and Jemperli for endometrial cancer), respiratory and immunology treatments (such as Nucala for asthma and COPD, and Trelegy for respiratory conditions), and other specialty therapeutic areas. These medicines typically address complex, chronic conditions and command premium pricing due to their specialized nature and limited competition. General Medicines comprises the remaining 40% of revenue, consisting of established pharmaceutical products including respiratory treatments, antibiotics, and other traditional medications. This segment includes widely-used treatments like Trelegy, an inhaled medicine for asthma and chronic obstructive pulmonary disease (COPD), which has become one of GSK's largest individual products with over £2 billion in annual sales.
Revenue model
GSK generates revenue through direct product sales to healthcare providers, governments, and distributors worldwide, operating under a traditional pharmaceutical business model where the company invests heavily in research and development, obtains regulatory approvals, and then sells patented medicines and vaccines at premium prices during the patent protection period. The company's revenue model varies by segment. Vaccines generate revenue through sales to government immunization programs, private healthcare providers, and direct-pay patients. Vaccine sales tend to be more predictable and less susceptible to generic competition due to the complex manufacturing processes and regulatory requirements. Specialty Medicines command higher margins due to their innovative nature, limited competition, and treatment of serious medical conditions where patients and insurers are willing to pay premium prices. General Medicines face more pricing pressure and generic competition but provide steady cash flow from established products. Several factors significantly impact GSK's profitability margins. Patent expiration represents the most significant threat, particularly the upcoming loss of exclusivity for Dolutegravir, a key HIV treatment, which management expects will require substantial mitigation through new product launches and productivity improvements. Regulatory decisions can dramatically affect sales, as seen with the RSV vaccine Arexvy facing challenges from U.S. Advisory Committee on Immunization Practices (ACIP) recommendations that limited its market potential. Healthcare policy changes, including the U.S. Inflation Reduction Act, are expected to reduce revenues by £400-500 million annually through Medicare drug price negotiations. Manufacturing complexity and scale provide both opportunities and challenges - vaccines and biologics require sophisticated production facilities that create barriers to entry but also represent significant capital investments. Currency fluctuations affect international sales, while competition from biosimilars and generic drugs continuously pressures pricing in mature product categories. R&D productivity remains crucial, as the company must consistently deliver new products to offset patent losses and maintain growth trajectories.
Competitive moat
GSK possesses a moderate but sustainable competitive moat built primarily around its specialized expertise in vaccine development and manufacturing, regulatory relationships, and established market positions in complex therapeutic areas. The company's strongest moat exists in its vaccines business, where GSK benefits from significant barriers to entry including complex manufacturing processes, extensive regulatory expertise, established relationships with government health agencies worldwide, and decades of safety data that competitors cannot easily replicate. Vaccine development requires specialized facilities, lengthy clinical trials, and deep regulatory knowledge that few companies possess. GSK's global vaccine infrastructure and established supply chains to government immunization programs create switching costs for customers. In specialty medicines, GSK's moat is more limited but still meaningful. The company has developed expertise in specific therapeutic areas like HIV, respiratory diseases, and oncology, building relationships with specialist physicians and establishing clinical evidence that supports premium pricing. The complexity of biologics manufacturing and the need for extensive clinical data create some barriers to competition, though these are not insurmountable. However, GSK faces significant competitive threats that limit its moat strength. Patent expiration remains the industry's fundamental challenge, with generic and biosimilar competition inevitably eroding pricing power. In HIV, competitors like Gilead Sciences pose ongoing threats with innovative treatments. The vaccine market faces competition from companies like Pfizer and Moderna, particularly as mRNA technology potentially disrupts traditional vaccine development approaches. Regulatory risk represents another moat limitation, as government agencies can significantly impact product uptake through recommendations and reimbursement decisions. The company's dependence on a relatively small number of key products also creates vulnerability - any safety issues or competitive threats to major products like Shingrix or Trelegy could materially impact the business. Overall, GSK's moat is moderate and defensible in the medium term but requires continuous innovation and successful product launches to maintain competitive positioning against well-funded pharmaceutical competitors and emerging biotechnology companies.
Risks & safety
GSK demonstrates strong financial stability with adequate liquidity and manageable debt levels, though some metrics warrant attention. Liquidity and Cash Position: - Cash and short-term investments: £4.7 billion as of Q1 2025 - Strong operating cash flow generation: £8.3 billion in 2024 - Free cash flow: £4.5 billion in 2024, demonstrating solid cash conversion - Current ratio of 0.87 indicates tight working capital management but adequate liquidity Debt and Solvency: - Debt-to-equity ratio of 1.24, indicating moderate leverage levels - Total liabilities of £60.1 billion against £75.5 billion in total assets - No immediate solvency concerns given strong cash generation - Investment-grade credit rating maintained Valuation Metrics: - Price-to-earnings ratio: 9.4 (Q1 2025), suggesting reasonable valuation - EV/EBITDA: 9.5, indicating moderate valuation relative to cash generation - Price-to-book ratio: 4.3, reflecting premium to book value typical for pharmaceutical companies - Graham number suggests potential undervaluation relative to historical metrics Other Considerations: - Significant legal contingencies related to Zantac litigation create potential downside risk - Patent cliff risks, particularly Dolutegravir expiration, require successful new product launches - Currency exposure from international operations adds volatility - Strong dividend coverage and progressive dividend policy indicate management confidence
Recent development
Over the past several years, GSK has undergone a strategic transformation from a diversified pharmaceutical company into a focused biopharmaceutical enterprise specializing in vaccines and specialty medicines. This transformation accelerated following the 2022 spinoff of the consumer healthcare business (now Haleon) and the company's rebranding from GlaxoSmithKline to GSK plc. The company has made significant pipeline investments with 13 positive Phase 3 clinical trial readouts in 2024 alone, focusing on 14 key assets with potential peak sales exceeding £2 billion each. Key pipeline developments include Depemokimab for severe asthma and COPD (offering potential six-month dosing intervals), Nucala's expansion into COPD treatment, and Blenrep's advancement in multiple myeloma treatment with demonstrated 33-month overall survival benefits. Strategic acquisitions and partnerships have strengthened GSK's capabilities, including the acquisition of IDRX to enhance oncology capabilities, collaborations with CureVac for mRNA-based influenza vaccines, and partnerships with Wave Life Sciences for oligonucleotide platform development. The company has also established manufacturing investments, breaking ground on a new facility in Marietta, Pennsylvania. Commercial execution has focused on expanding successful products globally, with Shingrix launched in 26+ countries targeting £4 billion peak sales, and Arexvy (RSV vaccine) approved in 39 countries despite initial market challenges. The HIV portfolio has evolved toward long-acting injectable treatments, with long-acting regimens now representing 55% of the HIV business. Capital allocation strategy has shifted toward shareholder returns and growth investments, with GSK announcing a £2 billion share buyback program while maintaining progressive dividend policy and continued R&D investment. The company has upgraded its 2031 sales outlook to more than £40 billion, reflecting confidence in the pipeline and commercial execution capabilities.
GSK company profile · for informational purposes only — not investment advice.
Track GSK with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free